CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.
Conference
"From Lab to Clinic: Potential Applications of Pharmacogenetics in HIV Clinical Practice" Dr. Anita Rachlis (biography) English - 2006-05-26 - 22 minutes
(14 slides)
Summary : In this presentation, Dr. Rachlis provides a brief overview of the current clinical trials and impediments of antiretroviral therapy.
Since the introduction of highly active antiretroviral therapy (HAART), progression to AIDS and death rates have significantly declined. It is generally accepted that HAART has contributed profoundly to our progress towards treating the disease. Despite these efforts numerous caveats remain. Toxicity, drug resistance, and clinical benefits of timing of therapy continue to challenge us and shape our choice of initial antiretroviral treatments. Other important considerations when selecting a drug regimen include flexibility, versatility, and adherence.
Various clinical trials have, and continue to assess, the efficacy of fixed dose regimens. These include: zidovudine/lamivudine, abacavir/lamivudine, tenofovir/emtricitabine, and zidovudine/lamivudine/abacavir. Of particular focus in this presentation are clinical studies investigating abacavir and tenofovir in fixed dose regimens.
In conclusion, Dr. Rachlis reviews the benefits and pitfalls of these fixed dose regimens. Overall, this presentation provides a thorough overview of current clinical trials and considerations for initiating HAART.
Learning objectives : After viewing this presentation, participants will be able to discuss:
- Efficacy of NRTI backbones;
- Toxicity of NRTI backbones.
Bibliographic references : Joel E. Gallant, M.D., M.P.H., Edwin DeJesus, M.D., José R. Arribas, M.D., Anton L. Pozniak, M.D., Brian Gazzard, M.D., Rafael E. Campo, M.D., Biao Lu, Ph.D., Damian McColl, Ph.D., Steven Chuck, M.D., Jeffrey Enejosa, M.D., John J. Toole, M.D., Ph.D., Andrew K. Cheng, M.D., Ph.D., for the Study 934 Group
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV N Engl J Med. 2006; 354:251-60
USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.
